drugset
drugset / Trial / NCT01611558

Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer

NCT01611558 ↗

Phase 2 Completed 40 enrolled Bristol-Myers Squibb
NaSingle-groupOpen-labelTreatment

Summary

To assess the incidence of drug-related adverse events of Grade 3 or higher and the overall response associated with ipilimumab treatment

Timeline

Start
2012-08-21
Primary completion
2014-11-03
Completion
2019-07-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Ipilimumab Monoclonal antibody 10 mg/kg Intravenous

Indications

No indication recorded.